Resources:

Find resources by:

Sort by:

Date Resource A-Z Random

Resources from the last:

Box size:

Filer text box:

Topic familiarity:

Grid Layout:

Collections that use this topic:

Collection topics:

Adrenal Bone Cardiovascular Diabetes Endocrine-Disrupting Chemicals Endocrine-Related Cancer Metabolism Neuroendocrinology Obesity Reproduction Steroid and Steroidogenesis Thyroid

Neuroendocrinology Somatostatin

Pituitary Brain Tumours Hypothalamus Kisspeptin ACTH TSH Cushing's NETs Paraganglioma Vasopressin Neuroendocrine Growth Somatostatin

New appropriate use criteria for somatostatin receptor PET imaging in NETs

Somatostatin neurons play a key role in controlling information flow

FDA approves new drug for carcinoid syndrome diarrhoea

Glucagonoma-induced acute heart failure

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors: CLARINET study

Co-Targeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumours

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study

18F-Fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumour origin and differentiation

Phase III results from ELECT study (NIH, 28 August 2013)

New trials in carcinoid cancer treatments commence (EurekAlert, 7 June 2013)

Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

Overweight? There’s a vaccine for that (AlphaGalileo, 6 July 2012)

EMA recommends approval of new somatostatin analogue pasireotide (Signifor) for Cushing’s disease (NeLM News Service, 20 January 2012)

EMA recommends approval of new somatostatin analogue pasireotide (Signifor) for Cushing’s disease (Reuters, 20 January 2012)

Regulation of glucose homeostasis

A study on glucagonoma

Comparing radionuclide imaging methods

Somatastatin, dopamine and their receptors in pituitary pathophysiology

Pituitary-independent effects of octreotide

CADTH to assess somatostatin analogues

Ipsen strikes alliance with the Erasmus University Medical Centre Rotterdam (Press release, 24 January 2007)

Ectopic ACTH syndrome: our experience with 25 cases

Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly

Chemoprevention of Pancreatic neuroendocrine tumours by somatostatin analogues

Challenges in acromegaly - resistance to somatostatin analogues

Somatostatin analogue therapy for acromegaly; what matters to patients?

A novel mechanism of effect for somatostatin analogues - the role of AIP

The ever-expanding role of somatostatin receptors in endocrine disease

Somatostatin analogue therapy in a patient with von Hippel-Lindau disease and multiple pancreatic ne...

Pegvisomant is more effective in stunting growth than somatostatin analogs in childhood acromegaly/gigantism.

Pharmacokinetics of Long Acting Somatostatin Analogue (Lanreotide) therapy in Hyperinsulinaemic Hypoglycaemia (HH) and understanding its molecular action via somatostatin receptors by Immunohistochemistry

Somatostatin-Expressing Cells Contribute To The Pathobiology Of Atypical Congenital Hyperinsulinism ...

T2-signal intensity, SST receptor expression and first-generation somatostatin analogues efficacy pr...

Postoperative use of somatostatin analogs and mortality in patients with acromegaly.

Somatostatin receptors: news in the pituitary, lessons for the periphery

Effects of Pegvisomant And Somatostatin Receptor Ligands On Risk Of Vertebral Fractures In Patients ...

The truncated somatostatin receptor sst5TMD4 is overexpressed in prostate cancer, where it increases...

Deciphering the antitumoral potential of stromal somatostatin receptor signal

AIP and the somatostatin signalling in pituitary tumours

Not so giants: mice lacking both somatostatin and cortistatin have high GH levels, but show no chang...

Medical Treatment of Acromegaly: Dual Blockade with a Somatostatin Analog and Pegvisomant

Ga-68-Dotatoc PET detects Somatostatin receptors in normal thyroids and various thyroid pathologies

sst2 gene transfer restores the somatostatin agonist sensitivity of human resistant pituitary adenom...

Somatostatin, cortistatin and their new and old receptors: from comparative to translational endocri...

DISEASE REMISSION IN LONG TERM TREATED ACROMEGALIC PATIENTS AFTER SOMATOSTATIN ANALOGS WITHDRAWAL.

Somatostatin analogues in the treatment of acromegaly: correlation between somatostatin receptor sub...

The use of Somatostatin Analogue and Novel use of Freestyle Libre ™ continuous blood sugar monitorin...

Survey of the Somatostatin Analogue use in the UK

Resource not read: Query You and Your Hormones

SEX-SPECIFIC ISLET HORMONE RELEASE BY GHSR1A ANTAGONIST LEAP2

177Lu-Dotatate in advanced midgut NETs

Long term pegvisomant for acromegaly

HYPOTHALAMIC LINKS BETWEEN GROWTH AND ENERGY BALANCE

SECOND-LINE TREATMENTS FOR GH- VERSUS GH&PRL-SECRETING TUMOURS IN ACROMEGALY

Three new endocrine drugs approved

MOLECULAR (FUNCTIONAL) IMAGING FOR PITUITARY ADENOMAS

Time for tea? Encouraging a support network among patients with acromegaly

THE BIRTH OF ENDOCRINOLOGY AND NEUROENDOCRINOLOGY

TECHNOLOGICAL ADVANCES IN NEUROENDOCRINE TUMOUR RESEARCH

Endocrine disorders with 'cat-titude'

Endocrinologist 154 Web Version

Endocrinologist 146 Web

Endocrinologist 144 Web

Endocrinologist 153 Web Version

The Endocrinologist 118 Web.pdf

Endocrinologist 123 Web

The Endocrinologist 117 Web.pdf

The Endocrinologist 114 Web.pdf

Endocrinologist 122 FINAL Web.pdf

Endocrinologist 138 Web

The Endocrinologist 115 Web FINAL.pdf

Endocrinologist 141 Web

Somatostatin analogs in the treatment of acromegaly: single centre experience

Unveiling the therapeutic role of somatostatin and cortistatin in prostate cancer

mRNA expression of somatostatin receptor subtypes in pheochromocytomas/paragangliomas

A novel mechanism of effect for somatostatin analogues: the role of AIP

Treatment of active acromegaly with the somatostatin analogue lanreotide SR

High-dose treatment with somatostatin analogues in neuroendocrine tumours

Role of filamin A in dopamine and somatostatin receptor targeting in the pituitary

Expression of somatostatin receptors in proliferating and quiescent endothelial cells

Postoperative use of somatostatin analogs and mortality in patients with acromegaly

Presence and pathophysiological role of sst5TMD4, an aberrant spliced variant of the somatostatin receptor subtype 5, in human high-grade astrocytomas

The effectiveness of yttrium90/lutetium177-labeled somatostatin analogues treatment in functional pNETs

Prevalence of cholelithiasis in somatostatin analogues treated Acromegaly patients

Somatostatin analogues in the treatment of acromegaly: correlation between somatostatin receptor subtype expression levels and clinical response

Detection of somatostatin receptors in aggressive non-functioning pituitary adenomas and effects of somatostatin analogs therapy in these tumors

Somatostatin receptor expression of gastroenteropancreatic neuroendocrine tumors: a comprehensive analysis of expression in the era of somatostatin receptor PET imaging

Secretion of Somatostatin and Growth Hormone (GH) in Various Forms of Hereditary Pathology

The role of immunohistochemical assessment of somatostatin receptor expression in case of patients with well differentiated neuroendocrine neoplasms with symptoms of carcinoid syndrome and negative somatostatin receptor imaging

Potential therapeutic role of somatostatin and cortistatin in prostate cancer

Somatostatin receptor splicing variant SST5TMD4 overexpression in glioblastoma is associated to poor survival, increased aggressiveness features and somatostatin analogs resistance

Somatostatin Analogue Treatment of a Persistant TSH-Secreting Adenoma: a report of case

Parenteral somatostatin analogues: a focus on injection site adverse reactions

Lesson learnt: severe skin reaction to somatostatin analogue injections

Effect of a modulation of somatostatin release on TSH secretion in healthy volunteers

BIM-23244, a somatostatin analogue with high affinity for somatostatin receptors 2 and 5, inhibits endothelial proliferation <i>in vitro</i>

Expression of somatostatin and dopamine receptors in neuroendocrine tumors: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores

Glucagon-like peptide-1 stimulates insulin secretion and then somatostatin secretion in rat islets

Prolonged remission of acromegaly after cessation of somatostatin analogue treatment

Endometriotic cell proliferation and survival are inhibited by somatostatin analogues and GHRH antagonists

Somatostatin analog therapy in advanced sporadic medullary thyroid carcinoma: a case report

A role for somatostatin in regulating weight regain after bariatric surgery in mice

Evaluation of somatostatin analogue-JQ1 conjugates for the treatment of pancreatic neuroendocrine tumours

Treatment with (177Lu)-DOTATATE in patients with advanced metastatic somatostatin receptor-positive tumors

Two cases of metastatic neuroendocrine tumours stabilised with somatostatin analogues

Interest of a single treatment by somatostatin analogues in a macroadenoma secreting TSH and GH

A somatostatin responsive, ACTH-secreting bronchial carcinoid- a diagnostic and therapeutic challenge

A somatostatin analogue and octreotide exert anti-proliferative effects on colonic cancer cells

Somatostatin analogues effectiveness in non-functioning pituitary adenomas in comparison with acromegaly

Somatostatin analogues treatment did not modify glucose control in acromegalic, diabetic subjects

Glucose resistance in acromegaly is reversible during somatostatin analogues treatment

Relationship between Insulin and somatostatin secretory response to Glucagon-like peptide-1 (GLP-1) and glucose concentration in perifused rat pancreatic islet cells

Pharmacokinetics of Long Acting Somatostatin Analogue (Lanreotide) Therapy in Hyperinsulinaemic Hypoglycaemia (HH) and Understanding its Molecular Action via Somatostatin Receptors by Immunohistochemistry

The expression and prognostic value of somatostatin and glucagon-like peptide 1 receptors in insulinoma

Effect of treatment with somatostatin analogue on glucose homeostasis in patients with acromegaly

Treatment with (177Lu)-dotatate in patients with advanced metastatic somatostatin receptor-positive tumors

8.15. Metastatic pheochromocytoma and paraganglioma: somatostatin receptor 2 expression, genetics, and therapeutic responses

Predictive factors of somatostatin receptor ligand response in acromegaly  a prospective study

Somatostatin receptors in olfactory neuroblastoma: The rationale for peptide receptor radionuclide therapy

Somatostatin-expressing cells contribute to the pathobiology of atypical congenital hyperinsulinism in infancy

A novel molecular subclassification may predict somatostatin analogs response in corticotropinomas

Use of Long Acting Somatostatin Analogue (Lanreotide) in Congenital Hyperinsulinism<sup>*</sup>

Acromegaly and Somatostatin Analogues: From Hospital to Home